Associations - FGFR mutation

FGFR mutation FGFR mutation	Urothelial Cancer Urothelial Cancer	FGFR mutation FGFR mutation	Urothelial Cancer Urothelial Cancer	erdafitinib Sensitive: A2 - Guideline	erdafitinib Sensitive: A2 - Guideline
FGFR mutation FGFR mutation	Urothelial Cancer Urothelial Cancer	FGFR mutation FGFR mutation	Urothelial Cancer Urothelial Cancer	pemigatinib Sensitive: C2 – Inclusion Criteria	pemigatinib Sensitive: C2 – Inclusion Criteria
FGFR mutation FGFR mutation	Pancreatic Cancer Pancreatic Cancer	FGFR mutation FGFR mutation	Pancreatic Cancer Pancreatic Cancer	pemigatinib Sensitive: C2 – Inclusion Criteria	pemigatinib Sensitive: C2 – Inclusion Criteria
FGFR mutation FGFR mutation	Urothelial Cancer Urothelial Cancer	FGFR mutation FGFR mutation	Urothelial Cancer Urothelial Cancer	erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials	erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials
FGFR mutation FGFR mutation	Urothelial Cancer Urothelial Cancer	FGFR mutation FGFR mutation	Urothelial Cancer Urothelial Cancer	FGFR inhibitor Sensitive: C3 – Early Trials	FGFR inhibitor Sensitive: C3 – Early Trials
FGFR mutation FGFR mutation	Solid Tumor Solid Tumor	FGFR mutation FGFR mutation	Solid Tumor Solid Tumor	ICP-192 Sensitive: C3 – Early Trials	ICP-192 Sensitive: C3 – Early Trials
FGFR mutation FGFR mutation	Cholangiocarcinoma Cholangiocarcinoma	FGFR mutation FGFR mutation	Cholangiocarcinoma Cholangiocarcinoma	ponatinib Sensitive: C3 – Early Trials	ponatinib Sensitive: C3 – Early Trials
FGFR mutation FGFR mutation	Cholangiocarcinoma Cholangiocarcinoma	FGFR mutation FGFR mutation	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: C3 – Early Trials	pemigatinib Sensitive: C3 – Early Trials
FGFR mutation FGFR mutation	Non Small Cell Lung Cancer NSCLC	FGFR mutation FGFR mutation	Non Small Cell Lung Cancer NSCLC	pemigatinib Sensitive: C3 – Early Trials	pemigatinib Sensitive: C3 – Early Trials
FGFR mutation FGFR mutation	Astrocytoma Astrocytoma	FGFR mutation FGFR mutation	Astrocytoma Astrocytoma	pemigatinib Sensitive: C3 – Early Trials	pemigatinib Sensitive: C3 – Early Trials
FGFR mutation FGFR mutation	Uterine Cancer Uterine Cancer	FGFR mutation FGFR mutation	Uterine Cancer Uterine Cancer	pemigatinib Sensitive: C3 – Early Trials	pemigatinib Sensitive: C3 – Early Trials
FGFR mutation FGFR mutation	Gallbladder Cancer Gallbladder Cancer	FGFR mutation FGFR mutation	Gallbladder Cancer Gallbladder Cancer	pemigatinib Sensitive: C3 – Early Trials	pemigatinib Sensitive: C3 – Early Trials
FGFR mutation FGFR mutation	Head and Neck Cancer Head and Neck Cancer	FGFR mutation FGFR mutation	Head and Neck Cancer Head and Neck Cancer	pemigatinib Sensitive: C3 – Early Trials	pemigatinib Sensitive: C3 – Early Trials
FGFR mutation FGFR mutation	Breast Cancer Breast Cancer	FGFR mutation FGFR mutation	Breast Cancer Breast Cancer	E7090 Sensitive: D – Preclinical	E7090 Sensitive: D – Preclinical